Skip to main content
Caplight Logo









Protego Biopharma

Protego Biopharma

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://protegobio.com/

Last Round

Series B

Dec 1, 2025

Total Funding Raised

$181M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Protego Biopharma is a biotechnology company that develops a small molecule therapeutics platform aimed at reprogramming protein folding to treat systemic amyloid diseases and other protein misfolding disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologysmall molecule therapeuticsdrug discoveryprotein misfoldingproteostasisbiopharmapharmacological chaperonedrug pipelinerare disease therapeuticsclinical-stage biotechprotein foldingprotein biophysicsbiotech startupdrug development pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Protego Biopharma Comparables

Compare Protego Biopharma with similar companies based on industry and business-model similarity.

Protego Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vicinitas Therapeutics
81%
Congruence Therapeutics
80%
Gain Therapeutics Inc
78%

Protego Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 1, 2025
Series ANov 17, 2021

Key People

Founding team and executive leadership

Christopher Weyrer

Chief Business Officer

Executive Team

Protego Biopharma Investors

Notable investors and investment history

Protego Biopharma investors
InvestorRounds
MPM CapitalSeed, Series A
Omega FundsSeries B
ForbionSeries B
Digitalis VenturesSeries B
Vida VenturesSeries B, Series A
MPM BioImpactSeries B
Droia VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 1, 2026

    Lead AL amyloidosis program advances to Phase III registrational trial.

  • Apr 27, 2026

    Open roles increased to 12, representing 50% of headcount.

Protego Biopharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Protego Biopharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Protego Biopharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range27
Year Founded2011
Last FundingDec 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?